Resources from the same session
LBA68 - Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)
Presenter: Nizar Tannir
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA73 - Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
Presenter: Jonathan Rosenberg
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Webcast
1447O - Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003
Presenter: Jaime Merchan
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1448O - Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
Presenter: Laurence Albiges
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1447O and 1448O
Presenter: Andre Fay
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Webcast